Objekt-Metadaten

Amelioration of intestinal and systemic sequelae of murine Campylobacter jejuni infection by probiotic VSL#3 treatment
Ekmekciu, Ira ;  Fiebiger, Ulrike ;  Stingl, Kerstin ;  Bereswill, Stefan ;  Heimesaat, Markus M.

HaupttitelAmelioration of intestinal and systemic sequelae of murine Campylobacter jejuni infection by probiotic VSL#3 treatment
AutorEkmekciu, Ira
AutorFiebiger, Ulrike
AutorStingl, Kerstin
AutorBereswill, Stefan
AutorHeimesaat, Markus M.
Seitenzahl13 S.
Freie SchlagwörterProbiotic compound; VSL#3; Secondary abiotic mice; Gnotobiotic mice; Bacterial in vivo competition; Pathogen–commensal bacteria–host interaction; Apoptosis; Innate and adaptive immune cells; Pro-inflammatory cytokines; Anti-inflammatory cytokines; Extra-intestinal and systemic sequelae of infection
DDC610 Medizin und Gesundheit
Auch erschienen inGut Pathogens. - 9 (2017), Artikel Nr. 17
ZusammenfassungBackground

The incidence of human Campylobacter jejuni infections is progressively increasing worldwide. Probiotic compounds might open up valuable tools to decrease pathogen burden and subsequent pro-inflammatory immune responses, but in vivo data are scarce.

Methods and results

Secondary abiotic mice generated by broad-spectrum antibiotic treatment were perorally challenged with the commercial probiotic compound VSL#3 consisting of Streptococcus thermophilus, Bifidobacterium breve, Bifidobacterium longum, Bifidobacterium infantis, Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus paracasei, and Lactobacillus delbrueckii ssp. bulgaricus) either 5 days before (i.e. prophylactic regimen) or after (i.e. therapeutic regimen) peroral C. jejuni strain 81–176 infection, and analyzed 3 weeks following the initial bacterial re-association. Upon challenge, mice were colonized with the probiotic bacteria and/or C. jejuni at comparable intestinal loads, but co-colonization did not result in reduction of the pathogen burden. Remarkably, prophylactic as well as therapeutic VSL#3 treatment of C. jejuni infected mice ameliorated intestinal apoptosis and pro-inflammatory immune responses as indicated by lower numbers of innate and adaptive immune cell populations in the murine colon upon probiotic prophylaxis or treatment and reduced colonic concentrations of pro-inflammatory mediators including IL-6 and MCP-1. Importantly, concentrations of anti-inflammatory mediators such as IL-10 were significantly elevated in the colon of probiotics treated mice as compared to untreated controls. Strikingly, prophylactic VSL#3 treatment attenuated C. jejuni induced systemic pro-inflammatory responses as indicated by less TNF and IL-12p70 secretion in the spleen of VSL#3 pre-treated as compared to non-treated mice.

Conclusion

Administration of probiotic formulations such as VSL#3 might open up valuable strategies for prophylaxis and/or treatment of C. jejuni induced intestinal and systemic sequelae in vivo by the suppression of pro-inflammatory and induction of anti-inflammatory responses.
Dokumente
PDF-Datei von FUDOCS_document_000000027027
Falls Ihr Browser eine Datei nicht öffnen kann, die Datei zuerst herunterladen und dann öffnen.
 
Fachbereich/EinrichtungMedizinische Fakultät Charité - Universitätsmedizin Berlin
Erscheinungsjahr2017
Dokumententyp/-SammlungenWissenschaftlicher Artikel
SpracheEnglisch
RechteCreative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Anmerkungen des AutorsDer Artikel wurde in einer reinen Open-Access-Zeitschrift publiziert.
Erstellt am18.05.2017 - 11:07:44
Letzte Änderung18.05.2017 - 11:11:59
 
Statische URLhttp://edocs.fu-berlin.de/docs/receive/FUDOCS_document_000000027027
DOI10.1186/s13099-017-0168-y
Zugriffsstatistik
 

LOADING...